Treatment of acne with antiandrogens--an evidence-based review (Q46809999)

25 December 2017

review article

1 reference

title

Treatment of acne with antiandrogens--an evidence-based review (English)

1 reference

25 December 2017

author name string

Christos C Zouboulis

series ordinal

1

1 reference

25 December 2017

language of work or name

German

0 references

publication date

1 July 2003

1 reference

25 December 2017

published in

JDDG

1 reference

25 December 2017

volume

1

1 reference

25 December 2017

issue

7

1 reference

25 December 2017

page(s)

535-546

1 reference

25 December 2017

Perceptions of acne vulgaris in final year medical student written examination answers

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Human skin: an independent peripheral endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Sebocytes are the key regulators of androgen homeostasis in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Update and future of hormonal therapy in acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Cutaneous androgen metabolism: basic research and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Acne therapy: a methodologic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Effect of low-dose oral contraceptives on androgenic markers and acne.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Update and future of systemic acne treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

The treatment of acne fulminans: a review of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Clinical application of 5alpha-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Net effect of oral contraceptive use on the risk of cancer in women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Medication and medical service utilization for acne 1995-1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Is acne vulgaris a genuine inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Mechanisms of androgen induction of sebocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

Topical spironolactone reduces sebum secretion rates in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1610-0387.2003.03011.X

10.1046/J.1610-0387.2003.03011.X

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16295039

1 reference

25 December 2017